Uterine atony: Difference between revisions
Jump to navigation
Jump to search
Adnan Ezici (talk | contribs) |
Adnan Ezici (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*In 1953, | *In 1953, Du Vigneaud et al. were the first to discover the [[aminoacid]] sequence of [[oxytocin]] and its biochemical synthesis.<ref name="pmid24259988">{{cite journal |vauthors=Prata N, Bell S, Weidert K |title=Prevention of postpartum hemorrhage in low-resource settings: current perspectives |journal=Int J Womens Health |volume=5 |issue= |pages=737–52 |date=2013 |pmid=24259988 |pmc=3833941 |doi=10.2147/IJWH.S51661 |url=}}</ref> | ||
* | *Following his discoveries about polypeptide hormones, The Nobel Prize for chemistry was awarded to Vincent du Vigneaud in 1955.<ref name="pmid17554806">{{cite journal |vauthors=Ragnarsson U |title=The Nobel trail of Vincent du Vigneaud |journal=J Pept Sci |volume=13 |issue=7 |pages=431–3 |date=July 2007 |pmid=17554806 |doi=10.1002/psc.864 |url=}}</ref> | ||
==Classification== | ==Classification== | ||
| Line 16: | Line 16: | ||
==Causes and Risk Factors== | ==Causes and Risk Factors== | ||
Common risk factors in the development of uterine atony include: | Common risk factors in the development of uterine atony include:<ref name="pmid23507549">{{cite journal |vauthors=Wetta LA, Szychowski JM, Seals S, Mancuso MS, Biggio JR, Tita AT |title=Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery |journal=Am J Obstet Gynecol |volume=209 |issue=1 |pages=51.e1–6 |date=July 2013 |pmid=23507549 |pmc=3788839 |doi=10.1016/j.ajog.2013.03.011 |url=}}</ref><ref name="pmid20142652">{{cite journal |vauthors=Oyelese Y, Ananth CV |title=Postpartum hemorrhage: epidemiology, risk factors, and causes |journal=Clin Obstet Gynecol |volume=53 |issue=1 |pages=147–56 |date=March 2010 |pmid=20142652 |doi=10.1097/GRF.0b013e3181cc406d |url=}}</ref><ref name="pmid19324236">{{cite journal |vauthors=Breathnach F, Geary M |title=Uterine atony: definition, prevention, nonsurgical management, and uterine tamponade |journal=Semin Perinatol |volume=33 |issue=2 |pages=82–7 |date=April 2009 |pmid=19324236 |doi=10.1053/j.semperi.2008.12.001 |url=}}</ref> | ||
*Uterine overdistention | *Uterine overdistention | ||
*Prolonged labor | **[[Polyhydramnios]] | ||
*Prolonged use of [[oxytocin]] | **[[multiple birth|Multiple pregnancy]] | ||
**[[large for gestational age|Macrosomia]] | |||
*Intrinsic factors | |||
**Advanced maternal age | |||
**Obesity | |||
**Maternal race/ethnicity (Hispanic and non-Hispanic white) | |||
**Previous [[postpartum hemorrhage]] | |||
**[[Anemia]] | |||
**[[Preeclampsia]] | |||
**[[Fibroids]] | |||
*[[Childbirth|Delivery]]-related factors | |||
**Prolonged labor | |||
**Precipitate labor | |||
**Prolonged use of [[oxytocin]] | |||
**Induction of labor | |||
**Manual removal of placenta | |||
*[[Chorioamnionitis]] | *[[Chorioamnionitis]] | ||
*[[ | *Administration of [[magnesium sulfate]] | ||
*[[volatile anesthetic| | *Administration of [[volatile anesthetic|inhaled anesthetic agents]] | ||
==Differentiating Uterine Atony from other Diseases== | ==Differentiating Uterine Atony from other Diseases== | ||
Uterine atony must be differentiated from other diseases that cause [[postpartum hemorrhage]], such as | Uterine atony must be differentiated from other diseases that cause [[postpartum hemorrhage]], such as retained [[placenta|placental]] tissue, obstetric [[lacerations]], placenta accreta spectrum ([[placenta accreta]], [[placenta accreta|increta]], and [[placenta accreta|percreta]]), uterine [[inversion]], [[bleeding diathesis|maternal coagulation defects]], and [[disseminated intravascular coagulation]] (DIC)<ref name="pmid17012482">{{cite journal |vauthors= |title=ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage |journal=Obstet Gynecol |volume=108 |issue=4 |pages=1039–47 |date=October 2006 |pmid=17012482 |doi=10.1097/00006250-200610000-00046 |url=}}</ref> | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
*Uterine atony is responsible for up to 80% of cases of [[postpartum hemorrhage]], and approximately 25% of [[maternal]] deaths are due to [[postpartum hemorrhage]], which is the leading cause of maternal deaths.<ref name="pmid23507549">{{cite journal |vauthors=Wetta LA, Szychowski JM, Seals S, Mancuso MS, Biggio JR, Tita AT |title=Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery |journal=Am J Obstet Gynecol |volume=209 |issue=1 |pages=51.e1–6 |date=July 2013 |pmid=23507549 |pmc=3788839 |doi=10.1016/j.ajog.2013.03.011 |url=}}</ref><ref name="pmid30625154">{{cite journal |vauthors=Fukami T, Koga H, Goto M, Ando M, Matsuoka S, Tohyama A, Yamamoto H, Nakamura S, Koyanagi T, To Y, Kondo H, Eguchi F, Tsujioka H |title=Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan |journal=PLoS One |volume=14 |issue=1 |pages=e0208873 |date=2019 |pmid=30625154 |pmc=6326562 |doi=10.1371/journal.pone.0208873 |url=}}</ref> | |||
==Screening== | |||
==References== | ==References== | ||
Revision as of 20:24, 20 May 2021
|
WikiDoc Resources for Uterine atony |
|
Articles |
|---|
|
Most recent articles on Uterine atony Most cited articles on Uterine atony |
|
Media |
|
Powerpoint slides on Uterine atony |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Uterine atony at Clinical Trials.gov Trial results on Uterine atony Clinical Trials on Uterine atony at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Uterine atony NICE Guidance on Uterine atony
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Uterine atony Discussion groups on Uterine atony Patient Handouts on Uterine atony Directions to Hospitals Treating Uterine atony Risk calculators and risk factors for Uterine atony
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Uterine atony |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]
Overview
Historical Perspective
- In 1953, Du Vigneaud et al. were the first to discover the aminoacid sequence of oxytocin and its biochemical synthesis.[1]
- Following his discoveries about polypeptide hormones, The Nobel Prize for chemistry was awarded to Vincent du Vigneaud in 1955.[2]
Classification
There is no established system for the classification of uterine atony.
Pathophysiology
It is thought that the uterine atony is caused by inadequate contraction of the myometrium following the delivery. Physiologically, contraction of the myometrium occurs in response to oxytocin, therefore, mediates the uterine hemostasis by mechanically compressing the blood vessels supplying the placenta.[3]
Causes and Risk Factors
Common risk factors in the development of uterine atony include:[4][5][6]
- Uterine overdistention
- Intrinsic factors
- Advanced maternal age
- Obesity
- Maternal race/ethnicity (Hispanic and non-Hispanic white)
- Previous postpartum hemorrhage
- Anemia
- Preeclampsia
- Fibroids
- Delivery-related factors
- Prolonged labor
- Precipitate labor
- Prolonged use of oxytocin
- Induction of labor
- Manual removal of placenta
- Chorioamnionitis
- Administration of magnesium sulfate
- Administration of inhaled anesthetic agents
Differentiating Uterine Atony from other Diseases
Uterine atony must be differentiated from other diseases that cause postpartum hemorrhage, such as retained placental tissue, obstetric lacerations, placenta accreta spectrum (placenta accreta, increta, and percreta), uterine inversion, maternal coagulation defects, and disseminated intravascular coagulation (DIC)[7]
Epidemiology and Demographics
- Uterine atony is responsible for up to 80% of cases of postpartum hemorrhage, and approximately 25% of maternal deaths are due to postpartum hemorrhage, which is the leading cause of maternal deaths.[4][8]
Screening
References
- ↑ Prata N, Bell S, Weidert K (2013). "Prevention of postpartum hemorrhage in low-resource settings: current perspectives". Int J Womens Health. 5: 737–52. doi:10.2147/IJWH.S51661. PMC 3833941. PMID 24259988.
- ↑ Ragnarsson U (July 2007). "The Nobel trail of Vincent du Vigneaud". J Pept Sci. 13 (7): 431–3. doi:10.1002/psc.864. PMID 17554806.
- ↑ Gill P, Patel A, Van Hook JW. PMID 29630290. Missing or empty
|title=(help) - ↑ 4.0 4.1 Wetta LA, Szychowski JM, Seals S, Mancuso MS, Biggio JR, Tita AT (July 2013). "Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery". Am J Obstet Gynecol. 209 (1): 51.e1–6. doi:10.1016/j.ajog.2013.03.011. PMC 3788839. PMID 23507549.
- ↑ Oyelese Y, Ananth CV (March 2010). "Postpartum hemorrhage: epidemiology, risk factors, and causes". Clin Obstet Gynecol. 53 (1): 147–56. doi:10.1097/GRF.0b013e3181cc406d. PMID 20142652.
- ↑ Breathnach F, Geary M (April 2009). "Uterine atony: definition, prevention, nonsurgical management, and uterine tamponade". Semin Perinatol. 33 (2): 82–7. doi:10.1053/j.semperi.2008.12.001. PMID 19324236.
- ↑ "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage". Obstet Gynecol. 108 (4): 1039–47. October 2006. doi:10.1097/00006250-200610000-00046. PMID 17012482.
- ↑ Fukami T, Koga H, Goto M, Ando M, Matsuoka S, Tohyama A, Yamamoto H, Nakamura S, Koyanagi T, To Y, Kondo H, Eguchi F, Tsujioka H (2019). "Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan". PLoS One. 14 (1): e0208873. doi:10.1371/journal.pone.0208873. PMC 6326562. PMID 30625154.